Literature DB >> 18067853

FGF-2 signaling induces downregulation of TAZ protein in osteoblastic MC3T3-E1 cells.

Homare Eda1, Katsuhiko Aoki, Keishi Marumo, Katsuyuki Fujii, Kiyoshi Ohkawa.   

Abstract

Transcriptional coactivator with PDZ-binding motif (TAZ) protein is a coactivator of Runx2 and corepressor of PPARgamma. It also induces differentiation of mesenchymal cells into osteoblasts. In this study, we found that FGF-2, which inhibits bone mineralization and stimulates cell proliferation, reduced the TAZ protein expression level in osteoblast-like cells, MC3T3-E1. This reduction was recovered by removing FGF-2 from the culture medium, which also restored the osteoblastic features of MC3T3-E1 cells. Furthermore, FGF-2-induced reduction of TAZ is blocked by a SAPK/JNK-specific inhibitor. These findings suggest that the expression of TAZ protein is involved in osteoblast proliferation and differentiation. This may help elucidate the discrepancies in the effect of FGF-2 and contribute to the understanding of FGF/FGFR-associated craniosynostosis syndrome etiology and treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067853     DOI: 10.1016/j.bbrc.2007.11.140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Regulation and function of the TAZ transcription co-activator.

Authors:  Chenying Liu; Wei Huang; Qunying Lei
Journal:  Int J Biochem Mol Biol       Date:  2011-07-20

2.  Stage-specific effects of fibroblast growth factor 2 on the differentiation of dental pulp cells.

Authors:  Karen Sagomonyants; Mina Mina
Journal:  Cells Tissues Organs       Date:  2015-03-25       Impact factor: 2.481

3.  Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation.

Authors:  Sumithra Urs; Deepak Venkatesh; Yuefeng Tang; Terry Henderson; Xuehui Yang; Robert E Friesel; Clifford J Rosen; Lucy Liaw
Journal:  FASEB J       Date:  2010-04-21       Impact factor: 5.191

4.  Regulation of myoepithelial differentiation.

Authors:  Renee F Thiemann; Scott Varney; Nicholas Moskwa; John Lamar; Melinda Larsen; Susan E LaFlamme
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

5.  Upregulation of Adipogenesis and Chondrogenesis in MSC Serum-Free Culture.

Authors:  Saey Tuan Barnabas Ho; Vivek Madhukar Tanavde; James Hoi Hui; Eng Hin Lee
Journal:  Cell Med       Date:  2011-06-01

6.  Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.

Authors:  Ling Jin; Yosuke Nonaka; Shin Miyakawa; Masatoshi Fujiwara; Yoshikazu Nakamura
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

Review 7.  Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.

Authors:  Taha Azad; Reza Rezaei; Abera Surendran; Ragunath Singaravelu; Stephen Boulton; Jaahnavi Dave; John C Bell; Carolina S Ilkow
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

8.  Combined effects of melatonin and FGF-2 on mouse preosteoblast behavior within interconnected porous hydroxyapatite ceramics - in vitro analysis.

Authors:  Mohammad Zeshaan Rahman; Hideo Shigeishi; Kazuki Sasaki; Akira Ota; Kouji Ohta; Masaaki Takechi
Journal:  J Appl Oral Sci       Date:  2016-04       Impact factor: 2.698

9.  FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways.

Authors:  Tadashi Kato; Atsushi Yamada; Mikiko Ikehata; Yuko Yoshida; Kiyohito Sasa; Naoko Morimura; Akiko Sakashita; Takehiko Iijima; Daichi Chikazu; Hiroaki Ogata; Ryutaro Kamijo
Journal:  FEBS Open Bio       Date:  2018-04-19       Impact factor: 2.693

Review 10.  Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.

Authors:  Yoshikazu Nakamura
Journal:  Cells       Date:  2021-06-28       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.